Pascolizumab

Pascolizumab is a humanized monoclonal antibody for the treatment of asthma.^[1] A Phase II clinical trial in patients with symptomatic glucocorticoid naive asthma was conducted in 2001/2002.^[2] Development was discontinued as it showed little benefit.^[3]

Pascolizumab

Monoclonal antibody
Type	Whole antibody
Source	Humanized (from mouse)
Target	IL-4
Clinical data
ATC code	none
Identifiers
CAS Number	331243-22-2 N
IUPHAR/BPS	7786
ChemSpider	none
UNII	N1IOA09R6A
NY (what is this?)  (verify)